Profile data is unavailable for this security.
About the company
AFYREN SA is a France-based company, which is primarily engaged in the environmental biotechnology. The Company focuses on the microbiology and bioprocess engineering that develops industrial process, named AFYNERIE, to convert non-food biomass to bioenergy. It provides measurement of the factory's methanogenic potential and laboratory analysis of waste, among others. It also allows to grow from a pilot stage to industrial-scale production that offers a wide panel of industries, bio sourced replacements with an environmentally friendly technology that uses natural microorganisms. AFYREN’s corporate culture works based on three core values that have driven the progress and laid the foundation for future achievements: commitment, agility and humility.
- Revenue in EUR (TTM)3.38m
- Net income in EUR-9.59m
- Incorporated2012
- Employees122.00
- LocationAFYREN SA9-11 rue GutenbergCLERMONT-FERRAND 63100FranceFRA
- Phone+33 473905116
- Websitehttps://afyren.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abionyx Pharma SA | 4.64m | -3.52m | 35.38m | 61.00 | -- | 4.43 | -- | 7.63 | -0.121 | -0.121 | 0.1581 | 0.246 | 0.3027 | 21.86 | 4.20 | 76,694.22 | -22.95 | -18.82 | -32.52 | -28.87 | 13.32 | 14.32 | -75.82 | -128.54 | 1.70 | -- | 0.2997 | -- | -11.65 | 92.84 | 16.36 | -- | 41.40 | -- |
| Groupe Berkem SA | 51.94m | 367.00k | 38.73m | 200.00 | 105.57 | 1.39 | 8.71 | 0.7457 | 0.0207 | 0.0207 | 2.92 | 1.57 | -- | -- | -- | 259,720.00 | -- | -- | -- | -- | 55.32 | -- | 0.7065 | -- | 0.8988 | 1.36 | 0.5798 | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| genOway SA | 18.63m | 1.59m | 39.88m | 124.00 | 23.71 | 2.34 | 9.94 | 2.14 | 0.1814 | 0.1814 | 2.12 | 1.84 | 0.5813 | 0.3881 | 2.50 | 142,180.80 | 4.98 | -0.5615 | 6.72 | -0.8058 | 97.61 | 93.72 | 8.56 | -1.12 | 2.10 | 17.42 | 0.3344 | -- | 21.64 | 11.57 | 341.09 | -16.63 | -18.02 | -- |
| Gensight Biologics SA | 1.27m | -26.22m | 40.14m | 16.00 | -- | -- | -- | 31.68 | -0.5427 | -0.5427 | 0.0269 | -0.4726 | 0.0723 | -- | 2,534.00 | 79,187.50 | -149.52 | -79.44 | -- | -144.54 | -- | -- | -2,069.53 | -1,036.27 | -- | -- | -- | -- | -50.93 | -- | 5.09 | -- | -58.28 | -- |
| Biosynex SA | 93.05m | -13.79m | 41.54m | 560.00 | -- | -- | -- | 0.4464 | -1.94 | -1.94 | -- | -- | -- | -- | -- | 248,141.30 | -- | 25.60 | -- | 33.90 | 25.22 | 51.82 | -13.15 | 20.26 | -- | -4.45 | -- | 14.72 | -48.61 | 45.12 | -84.99 | 118.26 | -- | -- |
| AbL Diagnostics SA | 11.19m | 1.20m | 48.99m | 19.00 | 5.07 | 7.30 | 161.45 | 4.38 | 0.5997 | 0.5997 | 5.58 | 0.4165 | 1.18 | -- | 5.21 | 588,990.50 | 12.67 | 8.99 | 26.09 | 10.77 | 35.76 | 38.29 | 10.75 | 31.17 | 1.28 | -- | 0.31 | 0.00 | -- | 67.89 | 328.77 | -- | -- | -- |
| GeNeuro SA | 0.00 | -14.76m | 55.06m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Valbiotis SA | 4.73m | -7.37m | 65.15m | 52.00 | -- | 3.32 | -- | 13.77 | -0.5904 | -0.5904 | 0.3798 | 1.24 | 0.1564 | 3.36 | 17.83 | 91,019.23 | -24.35 | -32.92 | -33.77 | -46.36 | 48.76 | 53.15 | -155.67 | -418.87 | 3.38 | -38.19 | 0.2598 | -- | 502.93 | 126.73 | 40.16 | -- | -21.71 | -- |
| AFYREN SA | 3.38m | -9.59m | 69.74m | 122.00 | -- | 1.13 | -- | 20.64 | -0.3696 | -0.3696 | 0.1303 | 2.37 | 0.0435 | -- | 5.39 | 27,696.72 | -12.35 | -9.58 | -13.42 | -10.46 | 92.63 | 95.57 | -283.69 | -162.61 | -- | -1.62 | 0.0719 | -- | -2.23 | -- | -4.20 | -- | -- | -- |
Data as of May 17 2024. Currency figures normalised to AFYREN SA's reporting currency: Euro EUR
11.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 29 Feb 2024 | 1.83m | 7.04% |
| OFI Invest Asset Management SAas of 29 Feb 2024 | 629.97k | 2.42% |
| Cr�dit Mutuel Asset Management SAas of 30 Jun 2023 | 135.00k | 0.52% |
| Sycomore Asset Management SAas of 28 Mar 2024 | 129.74k | 0.50% |
| Groupama Asset Management SAas of 29 Sep 2023 | 72.48k | 0.28% |
| CPR Asset Management SAas of 31 Mar 2024 | 52.34k | 0.20% |
| G�n�rali Investments Partners SpA SGR (France)as of 28 Feb 2022 | 37.10k | 0.14% |
| Meeschaert Asset Management SAas of 14 Sep 2023 | 4.00k | 0.02% |
| Union Bancaire Priv�e, UBP SA (UK)as of 17 Apr 2023 | 0.00 | 0.00% |
| Eleva Capital SASas of 31 Dec 2023 | 0.00 | 0.00% |
More ▼
Data from 29 Sep 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
